Downregulation of peroxiredoxin I by a novel fully human phage display recombinant antibody induces apoptosis and enhances radiation sensitization in A549 lung carcinoma cells

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 5, 2012, Pages 307-316

  Guo, Qishuai ^a   Huang, Xi ^b   Zhang, Jun ^a   Luo, Yi ^a   Peng, Zhiping ^a   Li, Shaolin ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b Hechuan District People's Hospital   (China)

Author keywords

human single chain variable fragment antibody; lung cancer; peroxiredoxin I; radiosensitivity

Indexed keywords

CASPASE 3; HISTONE H2AX; MONOCLONAL ANTIBODY SCFV; PEROXIREDOXIN 1; RAD51 PROTEIN; REACTIVE OXYGEN METABOLITE; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOMA CELL; CELL CYCLE G1 PHASE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LUNG CARCINOMA; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIZATION; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; PEPTIDE LIBRARY; PEROXIREDOXINS; RADIATION-SENSITIZING AGENTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862489824     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2011.0989     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA cancer J Clin 2009;59:225.
2. Lawenda BD, Kelly KM, Ladas EJ, et al. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst 2008;100:773.
3. Okunieff P, Swarts S, Keng P, et al. Antioxidants reduce consequences of radiation exposure. Adv Exp Med Biol 2008;614:165.
4. Kim HJ, Chae HZ, Kim YJ, et al. Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues. Cell Biol Toxicol 2003;19:285.
5. Chang JW, Jeon HB, Lee JH, et al. Augmented expression of Peroxiredoxin I in lung cancer. Biochem Biophy Res Commun 2001;289:507.
6. Chang JW, Lee SH, Jeong JY, et al. Peroxiredoxin I is an autoimmunogenic tumor antigen in non-small cell lung cancer. FEBS Lett 2005;579:2873.
7. Zhang B, Wang Y, Liu K, et al. Adenovirus-mediated transfer of siRNA against peroxiredoxin I enhances the radiosensitivity of human intestinal cancer. Biochem Pharmacol 2008;75:660.
8. Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007;6:349.
9. Piche A, Grim J, Rancourt C, et al. Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res 1998;58:2134.
10. Luo Y, Pang H, Li SJ, et al. Production and radioimmunoimaging of novel fully human phage display recombinant antibodies and growth inhibition of lung adenocarcinoma cell line overexpressing Prx I. Cancer Biol Ther 2009;8:1.
11. Huang ME, Rio AG, Nicolas A, et al. A genomewide screen in Saccharomyces cerevisiae for genes that suppress the accumulation of mutations. Proc Natl Acad Sci U S A 2003; 100:11529.
12. Huang ME, Kolodner RD. A biological network in Saccharomyces cerevisiae prevents the deleterious effects of endogenous oxidative DNA damage Mol Cell 2005;17:709.
13. Park SG, Cha MK, Jeong W, et al. Distinct physiological functions of thiol peroxidase isoenzymes in Saccharomyces cerevisiae. J Biol Chem 2000;275:5723.
14. Pedrajas JR, Miranda-Vizuete A, Javanmardy N, et al. Mitochondria of Saccharomyces cerevisiae contain one-conserved cysteine type peroxiredoxin with thioredoxin peroxidase activity. J Biol Chem 2000;275:16296.
15. Chen WC, McBride WH, Iwamoto KS, et al. Induction of radioprotective peroxiredoxin-I by ionizing irradiation. J Neurosci Res 2002;70:794.
16. Zhang B, Su Y, Ai G, et al. Involvement of peroxiredoxin I in protecting cells from IR-induced death. J Radiat Res 2005;46:305.
17. Zhang B, Wang Y, Su Y. Peroxiredoxins, a novel target in cancer radiotherapy. Cancer Lett 2009;286:154.
18. Neumann CA, Cao J, Manevich Y. Peroxiredoxin 1 and its role in cell signaling. Cell Cycle 2009;24:4072.
19. Rhee SG, Chae HZ, Kim K. Peroxiredoxins: A historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med 2005;38:1543.
20. Iraqui I, Kienda G, Soeur J, et al. Peroxiredoxin Tsa1 is the key peroxidase suppressing genome instability and protecting against cell death in Saccharomyces cerevisiae. PLoS Genetics 2009;6:e1000524.
21. Shinohara A, Ogawa H, Ogawa T. Rad51 protein involved in repair and recombination in S. cerevisiae is a RecA-like protein. Cell 1992;69:457.
22. Ohnishi T, Taki T, Hiraga S, et al. In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. Biochem Biophy Res Commun 1998;245:319.
23. Taki T, Ohnishi T, Yamamoto A, et al. Antisense inhibition of the RAD51 enhances radiosensitivity. Biochem Biophy Res Commun 1996;223:434.
24. Kuo LJ, Yang LX. Gamma-H2AX - A novel biomarker for DNA double- strand breaks. In Vivo 2008;22:305.
25. Chen MF, Keng PC, Shau H, et al. Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin 1 expression. Int J IR Oncology Biol Phys 2006;64:581.
26. Crombet T, Osorio M, Cruz T, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004;22:1646.
27. Buchsbaum DJ, Zhou T, Grizzle WE, et al. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or IR therapy in a human breast cancer model. Clin Cancer Res 2003;9: 3731.
28. Xiao J, Horst S, Hinkle G, et al. Pharmacokinetics and clinical evaluation of 125I-radiolabeled humanized CC49 monoclonal antibody in recurrent and metastatic colorectal cancer patients. Cancer Biother Radiopharm 2005;20:16.
29. Weiner LM. Fully human therapeutic monoclonal antibodies. J Immunother 2006;29:1.
30. Daugherty BL, DeMartino JA, Law MF, et al. Polymerase chain reaction facilitate the cloning, CDR-grafting and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins. Nucleic Acids Res 1991;19:2471.
31. Padlan EA. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol Immunol 1991;28:489.
32. Hoogenboom HR. Designing and optimizing library selection strategies for generating high-affinity antibodies. Trends Biotechnol 1997;15:62.
33. Vaughan TJ, Williams AJ, Pritchard K, et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 1996;14:309.
34. Park JW, Smolen J. Monoclonal antibody therapy. Adv Protein Chem 2001;56:369.